

Xintela proposes Hans-Joachim Simons as new Board member

Xintela AB (publ) proposes that the company's shareholders appoint Hans-Joachim Simons as a new member of the Board at the Annual General Meeting on May 6, 2022.

Hans-Joachim Simons (born 1962) is the founder and Managing Partner of Bluerock Healthcare Advisors, a dedicated healthcare consultancy firm, and has significant experience in the medtech-, biotech- and pharmaceutical industry. He has served in senior positions at Gambro AB, Karl Storz Endoscopy, as General Manager for Ivy Sports Medicine that was subsequently acquired by Stryker, and as a member of the Executive Board of Medical Park AG, a leading clinic group in Germany and for Codon AG, a cell therapy company in Berlin, Germany. He currently serves as a member of the Board of Arthromeda Inc. in Boston, USA.

Hans-Joachim holds an MD and PhD from the Heinrich-Heine-University in Düsseldorf, Germany and an executive MBA from the Business School of Stellenbosch University, South Africa. Hans-Joachim is qualified surgeon.

"I am delighted that Hans-Joachim has agreed to join our Board. With his long international experience in the industry, particularly in cell therapy and medtech marketing, he will add greatly to our capabilities in commercialisation, marketing and sales. Hans-Joachim will also work with our business development team on an executive basis to enhance our partnering and financing efforts", says Xintela's Chairman of the Board Gregory Batcheller.

Accordingly, the proposal to the Annual General Meeting is that the Board of Directors shall be composed of four Board members, without deputies, that the Board members Gregory Batcheller, Lars Hedbys and Maarten de Chateau are re-elected and that Hans-Joachim Simons is elected new member of the Board.

Contacts

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO

Tel: +46 46 275 65 00

Email: evy@xintela.se

Medicon Village

223 81 Lund, Sweden

www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin $\alpha 10\beta 1$ which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin $\alpha 10\beta 1$ (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

Attachments

[Xintela proposes Hans-Joachim Simons as new Board member](#)